Skip to content
Search

Latest Stories

Government warned of ‘very serious impact’ as antibiotic prices soar

The PSNC on Friday said it has warned the DHSC about the “very serious impact” of the limited supply of certain antibiotics on pharmacies who are “having to chase stock, purchase without sight of any concession prices, and cope with increasing patient questions and abuse.”

With higher than usual number of cases of scarlet fever, caused by invasive Group A Streptococci (iGAS) infections, being reported in children across the country, supplies of antibiotics for Group A Strep treatment have seen a surge in demand, leading to limited supply at certain wholesalers and pharmacies.


PSNC has urged the DHSC to adopt measures that could help to manage the current crisis, such as allowing pharmacists more freedom to change strengths or formulations without prescriber approval, outside of Serious Shortage Protocols.

It has also raised concerns on the significant rise in wholesale prices of many oral antibiotics as a result of the surge in demand and the ongoing supply disruptions. PSNC also said they have received reports of some suppliers putting up their prices for any oral antibiotics they do have in stock.

“The accounts we are getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis. We expect to see a record number of concessions granted this month which is yet more proof that this system is simply not coping with the current medicines market,” Janet Morrison, PSNC chief executive, said.

Due to pricing issues affecting several medicines including antibiotics, PSNC said it has applied for a record number of price concessions this month.

“We are very concerned that many contractors who are desperately trying to get hold of limited stock of antibiotics for their patients are paying inflated prices for these medicines without any certainty of their final reimbursement prices,” the organisation said in an update.

“We have reiterated that the pricing situation is very serious and needs resolving urgently, and asked the department to fast-track concessions for affected antibiotics this month.”

Dervis Gurol, who runs the Healthy-U Pharmacy in Saltdean, near Brighton, alleged of “extortion” after he was charged £11 for a penicillin mixture for which he expects to get just over £2 from the NHS.

“We don’t have any alternative, my loss this week just on antibiotics is over £3,000. The wholesalers don’t justify anything and I do think some are taking advantage of the situation. Some wholesalers were charging £11.78 for a bottle and we get reimbursed at £2.08,” he told The Times.

“Most of us are in a situation where we’re using our own money to operate and trying to absorb these costs that should be absorbed by the NHS. The Department of Health is refusing to do anything about the wholesalers.”

The paper reported that some wholesalers have increased the price of antibiotics such as amoxicillin and penicillin by up to five times.

Arun Jangra, who runs the Merlin Pharmacy in Kent, told that paper that it was taking him hours every day to source medications. He said he was quoted prices of more than £7 for a packet of antibiotics.

“A lot of companies are taking advantage,” he said, adding: “At times like this the government does not help and actually make things worse by telling people there’s no shortage.”

He said he was forced to call police last week after a patient demanded two bottles of antibiotics that Jangra could not supply. The man told him: “I know there are loads of antibiotics because the government has said so on the radio.”

PSNC said it has told the DHSC that more communications are needed to reassure patients and to protect pharmacy staff from the abuse that they are reporting.

“[The] government and the NHS have squeezed pharmacies dry financially, and now they want us to pay their NHS drugs bill as well: it just cannot carry on. The department, NHS and [the] government need to hear and understand that we are on our knees and cannot continue to pay for the mess that a combination of Brexit, COVID, inflationary pressures, war in Ukraine and other factors has caused,” Morrison added.

“I will be taking all of this to my meeting with the Minister [this] week, and in the meantime we’re continuing to press for a fairer and more timely system to protect pharmacies from these devastating price rises.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less